Validation-based insertional mutagenesis identifies lysine demethylase FBXL11 as a negative regulator of NFκB

Proceedings of the National Academy of Sciences of the United States of America

Volumn 106, Issue 38, 2009, Pages 16339-16344

  Lu, Tao ^a   Jackson, Mark W ^b   Singhi, Aatur D ^a   Kandel, Eugene S ^c   Yang, Maojing ^a   Zhang, Yi ^d,e   Gudkov, Andrei V ^c   Stark, George R ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

^b CASE WESTERN RESERVE UNIVERSITY   (United States)

^c ROSWELL PARK CANCER INSTITUTE   (United States)

^d UNIVERSITY OF NORTH CAROLINA   (United States)

^e UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

Cre recombinase; Lentivirus; Promoter insertion

Indexed keywords

DNA; F BOX LEUCINE RICH PROTEIN 11; GUANINE NUCLEOTIDE BINDING PROTEIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; LYSINE DEMETHYLASE; METHYLTRANSFERASE; SMALL INTERFERING RNA; UNCLASSIFIED DRUG; VSV G PROTEIN;

ANIMAL CELL; ARTICLE; CONTROLLED STUDY; ENZYME ACTIVITY; GENE EXPRESSION; GENE INSERTION; GENE LOCUS; GENE MUTATION; GENOME; MUTAGENESIS; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; VALIDATION STUDY;

ANTIBIOTICS, ANTINEOPLASTIC; BLEOMYCIN; BLOTTING, NORTHERN; BLOTTING, WESTERN; CELL LINE; CELL SURVIVAL; F-BOX PROTEINS; GENETIC VECTORS; GREEN FLUORESCENT PROTEINS; HISTONES; HT29 CELLS; HUMANS; LYSINE; METHYLATION; MICROSCOPY, FLUORESCENCE; MUTAGENESIS, INSERTIONAL; MUTATION; NF-KAPPA B; OXIDOREDUCTASES, N-DEMETHYLATING; RECOMBINANT FUSION PROTEINS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, SMALL INTERFERING; TRANSFECTION;

LENTIVIRUS; MAMMALIA; VESICULAR STOMATITIS VIRUS;

EID: 70349490830     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.0908560106     Document Type: Article

References (23)

1. Berns K, et al. (2004) A large-scale RNAi screen in human cells identifies new components of the p53 pathway. Nature 428:431-437. (Pubitemid 38419689)
2. Gudkov AV, Kazarov AR, Thimmapaya R, Axenovich SA, Mazo IA, Roninson IB (1994) Cloning mammalian genes by expression selection of genetic suppressor elements: Association of kinesin with drug resistance and cell immortalization. Proc Natl Acad Sci USA 91:3744-3748. (Pubitemid 24139508)
3. Kandel ES, Stark GR (2003) Forward genetics in mammalian cells. In Signal transducers and activators of transcription (STATs): Activation Biology, eds Seghal PB, Levy DE, Hirano T (Kluwer, Dordrecht, The Netherlands).
4. Stark GR, Gudkov AV (1999) Forward genetics in mammalian cells: Functional approaches to gene discovery. Hum Mol Genet 8:1925-1938. (Pubitemid 29458671)
5. Kandel ES, Lu T, Wan Y, Agarwal MK, Jackson MW, Stark GR (2005) Mutagenesis by reversible promoter insertion to study the activation of NFκB. Proc Natl Acad Sci USA 102:6425-6430. (Pubitemid 40617459)
6. Karin M, Yamamoto Y, Wang QM (2004) The IKK NFκB system: A treasure trove for drug development. Nat Rev Drug Discov 3:17-26. (Pubitemid 38088695)
7. Karin M (2006) Nuclear factor κB in cancer development and progression. Nature 441:431-436. (Pubitemid 44050137)
8. Baldwin AS (2001) Control of oncogenesis and cancer therapy resistance by the transcription factor NFκB. J Clin Invest 107:241-246.
9. Lu T, Sathe SS, Swiatkowski SM, Hampole CV, Stark GR (2004) Secretion of cytokines and growth factors as a general cause of constitutive NFκB activation in cancer. Oncogene 23:2138-2145. (Pubitemid 38482528)
10. Lu T, et al. (2004) Secreted transforminggrowthfactor β2 activates NFκB, blocks apoptosis, and is essential for the survival of some tumor cells. Proc Natl Acad Sci USA 101:7112-7117. (Pubitemid 38596451)
11. Li X, Commane M, Burns C, Vithalani K, Cao Z, Stark GR (1999) Mutant cells that do not respond to interleukin-1 (IL-1) reveal a novel role for IL-1 receptor-associated kinase. Mol Cell Biol 19:4643-4652. (Pubitemid 29289502)
12. Sathe SS, et al. (2004) Mutant human cells with constitutive activation of NFκB. Proc Natl Acad Sci USA 101:192-197. (Pubitemid 38084226)
13. Tsukada Y, et al. (2006) Histone demethylation by a family of JmjC domain-containing proteins. Nature 439:811-816. (Pubitemid 43255695)
14. Deuschle U, Meyer WK, Thiesen HJ (1995) Tetracycline-reversible silencing of eukaryotic promoters. Mol Cell Biol 15:1907-1914.
15. Mitchell RS, et al. (2004) Retroviral DNA integration: ASLV, HIV, and MLV show distinct target site preferences. PLoS Biol 2:E234.
16. Wu X, Li Y, Crise B, Burgess SM (2003) Transcription start regions in the human genome are favored targets for MLV integration. Science 300:1749-1751. (Pubitemid 36712571)
17. Gaide O, et al. (2002) CARMA1 is a critical lipid raft-associated regulator of TCR-induced NFκB activation. Nat Immunol 3:836-843. (Pubitemid 35049434)
18. Wald D, et al. (2003) SIGIRR, a negative regulator of Toll-like receptor-interleukin 1 receptor signaling. Nat Immunol 4:920-927. (Pubitemid 37098664)
19. Jiang Y, Woronicz JD, Liu W, Goeddel DV (1999) Prevention of constitutive TNF receptor 1 signaling by silencer of death domains. Science 283:543-546. (Pubitemid 129504622)
20. Beyaert R, Heyninck K, Van Huffel S (2000) A20 and A20-binding proteins as cellular inhibitors of nuclear factor κB-dependent gene expression and apoptosis. Biochem Pharmacol 60:1143-1151.
21. Heyninck K, Beyaert R (2005) A20 inhibits NFκB activation by dual ubiquitin-editing functions. Trends Biochem Sci 30:1-4. (Pubitemid 40093732)
22. Carmody RJ, Ruan Q, Palmer S, Hilliard B, Chen YH (2007) Negative regulation of toll-like receptor signaling by NFκB p50 ubiquitination blockade. Science 317:675-678. (Pubitemid 47229968)
23. Wiznerowicz M, Trono D (2003) Conditional suppression of cellular genes: Lentivirus vector-mediated drug-inducible RNA interference. J Virol 77:8957-8961. (Pubitemid 36936105)